{"title":"<i>Akkermansia muciniphila</i> in patients with metabolic dysfunction-associated steatotic liver disease.","authors":"Adina Ioana Mihele, Liviu Lazar","doi":"10.25122/jml-2024-0342","DOIUrl":null,"url":null,"abstract":"<p><p><i>Akkermansia muciniphila</i> (AM), one of the many microbial species residing in the human gut, has been particularly highlighted for its potential beneficial impacts on host metabolism and gut barrier function. This study evaluated the association between AM concentration and metabolic markers among patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASL). The study included a cohort of 122 patients with MASLD, monitored between January 1 and June 30, 2024, at the Venus Vascular Center in Oradea, Romania. Enterotype 2 was predominant in the study population, accounting for over 60% of participants. Correlation analysis revealed no statistically significant association between alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels and AM concentration (ALT: r = -0.147, <i>P</i> = 0.105; AST: r = -0.090, <i>P</i> = 0.325). However, a significant negative linear correlation was determined between gamma-glutamyl transferase (GGT) values and AM concentrations (r = -0.314, <i>P</i> < 0.001) and a moderate, positive correlation between high-density lipoprotein (HDL) values and AM concentration (r = 0.307, <i>P</i> < 0.001). Glycemia showed a weak negative correlation with AM concentration (r = -0.262, <i>P</i> = 0.003). The improvement of liver markers (AST, ALT), even in the absence of correlation with AM concentration, and the negative correlation of GGT, a marker for hepatobiliary diseases and metabolic syndrome, suggest the reduction of oxidative stress in MASLD.</p>","PeriodicalId":16386,"journal":{"name":"Journal of Medicine and Life","volume":"17 9","pages":"880-885"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11611053/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicine and Life","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.25122/jml-2024-0342","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Akkermansia muciniphila (AM), one of the many microbial species residing in the human gut, has been particularly highlighted for its potential beneficial impacts on host metabolism and gut barrier function. This study evaluated the association between AM concentration and metabolic markers among patients diagnosed with metabolic dysfunction-associated steatotic liver disease (MASL). The study included a cohort of 122 patients with MASLD, monitored between January 1 and June 30, 2024, at the Venus Vascular Center in Oradea, Romania. Enterotype 2 was predominant in the study population, accounting for over 60% of participants. Correlation analysis revealed no statistically significant association between alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels and AM concentration (ALT: r = -0.147, P = 0.105; AST: r = -0.090, P = 0.325). However, a significant negative linear correlation was determined between gamma-glutamyl transferase (GGT) values and AM concentrations (r = -0.314, P < 0.001) and a moderate, positive correlation between high-density lipoprotein (HDL) values and AM concentration (r = 0.307, P < 0.001). Glycemia showed a weak negative correlation with AM concentration (r = -0.262, P = 0.003). The improvement of liver markers (AST, ALT), even in the absence of correlation with AM concentration, and the negative correlation of GGT, a marker for hepatobiliary diseases and metabolic syndrome, suggest the reduction of oxidative stress in MASLD.
嗜粘杆菌(Akkermansia muciniphila, AM)是人类肠道中众多微生物之一,因其对宿主代谢和肠道屏障功能的潜在有益影响而受到特别关注。本研究评估了代谢功能障碍相关脂肪变性肝病(MASL)患者AM浓度与代谢标志物之间的关系。该研究包括122名MASLD患者,于2024年1月1日至6月30日在罗马尼亚奥拉迪亚金星血管中心进行监测。2型肠型在研究人群中占主导地位,占参与者的60%以上。相关分析显示,谷丙转氨酶(ALT)和天冬氨酸转氨酶(AST)水平与AM浓度无统计学意义(ALT: r = -0.147, P = 0.105;AST: r = -0.090, P = 0.325)。然而,γ -谷氨酰转移酶(GGT)值与AM浓度之间呈显著的负线性相关(r = -0.314, P < 0.001),高密度脂蛋白(HDL)值与AM浓度之间呈中度正相关(r = 0.307, P < 0.001)。血糖与AM浓度呈弱负相关(r = -0.262, P = 0.003)。肝脏标志物(AST, ALT)的改善,即使与AM浓度没有相关性,以及肝胆疾病和代谢综合征标志物GGT的负相关,提示MASLD中氧化应激的减少。
期刊介绍:
The Journal of Medicine and Life publishes peer-reviewed articles from various fields of medicine and life sciences, including original research, systematic reviews, special reports, case presentations, major medical breakthroughs and letters to the editor. The Journal focuses on current matters that lie at the intersection of biomedical science and clinical practice and strives to present this information to inform health care delivery and improve patient outcomes. Papers addressing topics such as neuroprotection, neurorehabilitation, neuroplasticity, and neuroregeneration are particularly encouraged, as part of the Journal''s continuous interest in neuroscience research. The Editorial Board of the Journal of Medicine and Life is open to consider manuscripts from all levels of research and areas of biological sciences, including fundamental, experimental or clinical research and matters of public health. As part of our pledge to promote an educational and community-building environment, our issues feature sections designated to informing our readers regarding exciting international congresses, teaching courses and relevant institutional-level events.